- Oops!Something went wrong.Please try again later.
RADNOR, Pa., Sept. 22, 2021 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of shareholders of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) (“Protagonist”).
Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from its proprietary technology platform. Protagonist’s pipeline includes rusfertide (PTG-300).
On September 17, 2021, Protagonist issued a press release “announc[ing] the receipt of a verbal communication from the U.S. Food and Drug Administration (FDA) that Protagonist's clinical studies for rusfertide, an investigational product candidate currently in development, have been placed on a clinical hold.” The press release further stated that “[t]he clinical hold follows Protagonist’s notification to the FDA of a recent non-clinical finding in a 26-week rasH2 transgenic mouse model study. The rasH2 model is designed to detect signals related to tumorigenicity, and benign and malignant subcutaneous skin tumors were observed in this study.”
Following this news, Protagonist’s stock price fell $28.60 per share, or 62%, to close at $17.53 per share on September 17, 2021.
If you are a Protagonist investor and would like to learn more about our investigation, please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484) 270-1453; toll free at (844) 887-9500; via e-mail at email@example.com; or please visit the following link to fill out our online form: https://www.ktmc.com/protagonist-therapeutics-inc-investigation?utm_source=PR&utm_medium=link&utm_campaign=protagonist_therapeutics
Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com.
Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
280 King of Prussia Road
Radnor, PA 19087